Cyclic peptidomimetic for the treatment of neurological disorders

Patent metadata

Field	Value
Publication number	US-12240920-B2
Application number	US-202318531607-A
Country	US
Kind code	B2
Filing date	Dec 6, 2023
Priority date	Oct 2, 2019
Publication date	Mar 4, 2025
Grant date	Mar 4, 2025

Abstract

The present invention provides to compositions and methods useful in the treatment of neurological disorders including, but not limited to, Angelman syndrome, depression, traumatic brain injury, stroke, and Alzheimer's disease. CN2097, a rationally designed cyclic peptidomimetic drug that has been demonstrated to have effectiveness in preclinical models for the treatment of neurological disorders, is rapidly cleared and has a short half-life. The present invention provides a stable analog of CN2097.

First claim

What is claimed is:

1. A composition comprising a therapeutically effective amount of dR 7 -2097 or a pharmaceutically acceptable salt thereof, wherein the dR 7 -2097 comprises RRRRRRRC (SEQ ID NO: 2 or PolyArg) in the following dR 7 -2097 structure:

wherein the PolyArg consists of all the R enantiomer, (R)-Arg or (“R”)-arginine, and all the S enantiomer, (“S”)-cysteine amino acids in the RRRRRRRC (SEQ ID NO: 2); and
wherein in the dR 7 -2097 there is a disulfide linkage from the(S)-Cys or (“S”)-cysteine to one (R)-Cys or (“R”)-cysteine.

2. The composition of claim 1 , wherein the PolyArg (or SEQ ID NO: 2) is operative to transport the dR 7 -2097 across a blood-brain barrier (BBB) in a subject who has been administered said composition.

3. The composition of claim 2 , wherein the dR 7 -2097 is at least four times more efficacious than CN2097 in treating a neurological disorder in said subject; and wherein the neurogical disorder is a major depressive disorder.

4. The composition of claim 1 , further comprising at least one pharmaceutically acceptable carrier.

5. The composition of claim 1 , wherein the pharmaceutically acceptable salt thereof comprises 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, l-ascorbic acid, I-aspartic acid, benzenesulfonic acid, benzoic acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, d-glucoheptonic acid, d-gluconic acid, d-glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, I-malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, I-pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, I-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, or an undecylenic acid salt.

6. The composition of claim 1 , wherein the pharmaceutically acceptable salt thereof further comprises a solvate and/or a hydrate.

Assignees

• Univ Brown

Inventors

• Marshall John

Classifications

• A61P25/24 Primary

  Antidepressants · CPC title

• A61P25/22

  Anxiolytics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07K7/56

  the cyclisation not occurring through 2,4-diamino-butanoic acid · CPC title